The UK and US have signed a significant bilateral deal that will maintain zero import taxes on UK medicine shipments being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This move ensures that import taxes on these vital goods will remain at nothing for a period of 36 months.
This agreement comes after recent statements to hike tariffs on branded pharmaceutical products, with potential rates mentioned reaching 100%.
"This agreement between the United Kingdom strengthens the international landscape for cutting-edge drugs and brings much-needed balance to U.S.–U.K. medicine commerce," a release declared.
Commercial Importance
Medicines are one of the UK's largest goods shipped to the United States, which is easily the biggest market for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of last September, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure accounted for 17.4% of total UK exports in that period.
"This guarantee safeguards work, increases investment and facilitates the UK to become a worldwide center for medical research," a minister remarked.
Specific British Pledges
The agreement involves several notable changes from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Last year, refunds topped twenty percent.
Recent Tensions
The deal follows a protracted dispute between the drug companies and the British authorities over medicine costs and approval rates.
The disagreement were exacerbated by claims that US customers were charged several times more for the same drugs than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the past decade.
